Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Support

This activity is supported by educational grants from BeiGene, Ltd and Pharmacyclics.

Advances In™ Waldenstrom Macroglobulinemia: Navigating Novel BTK Inhibitors and Beyond

Release Date: July 28, 2021
Expiration Date: July 28, 2022

Activity Overview

Waldenström macroglobulinemia (WM) is a rare lymphoproliferative disorder characterized by the infiltration of lymphoplasmacytic cells in bone marrow and the presence of immunoglobulin M (IgM) protein. The discovery of the MYD88 mutation, found in up to 97% of patients with WM, and the approval of Bruton’s tyrosine kinase (BTK) inhibitors to treat the disease has transformed how hematologists approach the disease. In this program, experts explore the available BTK inhibitors, examine recent clinical study data regarding their efficacy and safety, including their use as part of combination regimens, and look at emerging therapies including this drug class.

Acknowledgement of Commercial Support

This activity is supported by educational grants from BeiGene, Ltd and Pharmacyclics.

Instructions for This Activity and Receiving Credit

  1. Complete the activity (including pre- and post-activity assessments).
  2. Answer the evaluation questions.
  3. Request credit using the drop-down menu.

You may immediately download your certificate.

Target Audience

This activity is directed toward oncologists and hematologists involved in the treatment and management of Waldenström macroglobulinemia (WM). Fellows, nurses, nurse practitioners, physician assistants, and other health care professionals involved in the management of patients with WM will also be invited to participate.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

  • Explain the rationale underlying the use of Bruton’s tyrosine kinase (BTK) inhibitors for the treatment of Waldenström macroglobulinemia (WM)
  • Describe recent clinical trial data regarding the efficacy and safety of emerging therapies for the treatment of WM
  • Identify treatment-related toxicities from recent clinical trials and methods to mitigate their impact on clinical outcomes among patients with WM
  • Discuss potential changes to the treatment landscape following the latest data from clinical trials evaluating therapies for the treatment of WM

Faculty, Staff, and Planners’ Disclosures

The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible entities.


Steven Treon, MD, PhD, FACP, FRCP
Steven Treon, MD, PhD, FACP, FRCP
Harvard Medical School
Director, Lead Physician
Bing Center for Waldenstrom’s Macroglobulinemia
Dana-Farber Cancer Institute
Boston, MA

Disclosures: Grant/Research Support: AbbVie, BeiGene; Consultant: BeiGene, Janssen Pharmaceuticals, Pharmacyclics.

Jorge J. Castillo, MD
Jorge J. Castillo, MD
Senior Physician
Dana-Farber Cancer Institute
Clinical Director
Bing Center for Waldenstrom’s Macroglobulinemia
Associate Professor
Harvard Medical School
Boston, MA

Disclosures: Grant/Research Support: AbbVie, BeiGene, Pharmacyclics, TG Therapeutics; Consultant: AbbVie, BeiGene, Janssen Pharmaceuticals, Pharmacyclics, Roche.

PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.

Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
Filter By